Back to top
more

Endo International plc (ENDP)

(Delayed Data from NSDQ)

$8.20 USD

8.20
3,004,238

+0.48 (6.22%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Why Is Endo (ENDP) Down 10.6% Since the Last Earnings Report?

Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Will Endo's Troubles Continue to Dent Performance in 2017?

    2017 will continue to challenging for Endo Pharmaceuticals (ENDP) as the generics base business and the legacy branded pain franchise are expected to decline further.

      VIVUS to Regain Commercial Rights for Stendra from Sanofi

      VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.

        BioDelivery (BDSI) Q4 Loss Wider Than Expected; Sales Meet

        BioDelivery Sciences International, Inc. (BDSI) reported loss of 29 cents per share in the fourth quarter of 2016, slightly wider than the Zacks Consensus Estimate of a loss of 28 cents.

          Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA

          Endo International plc (ENDP) announced that the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees had consented that the benefits of reformulated Opana ER no longer outweigh its risks.

            New Strong Sell Stocks for March 9th

            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

              Why Endo International (ENDP) Could Be Positioned for a Slump

              One stock that you may want to consider dropping is Endo International plc (ENDP), which has witnessed a significant price decline in the past four weeks.

                Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low

                Endo's (ENDP) Q4 results beat expectations but the outlook for 2017 was disappointing and lagged expectations

                  Ekta Bagri headshot

                  Endo (ENDP) Q4 Earnings & Revenues Beat Estimates

                  Endo (ENDP) surpassed fourth-quarter 2016 earnings

                    Tracey Ryniec headshot

                    Start the Week with the Best Earnings Charts

                    These earnings giants are crushing it every quarter.

                      Implied Volatility Surging for Endo International (ENDP) Stock Options

                      Options traders are pricing in a big move for Endo International (ENDP) shares as it has huge implied volatility.

                        Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?

                        Endo International plc (ENDP) is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell.

                          Endo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval

                          Endo International plc (ENDP) announced that Par Pharmaceutical has received final approval from the FDA regarding its New Drug Application (NDA) for ephedrine sulfate injection.

                            Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)

                            Endo International plc (ENDP) announced that it has begun restructuring its corporate and branded pharmaceutical R&D functions in Malvern, PA and Chestnut Ridge, NY.

                              Endo (ENDP) Restructures its Branded Pharmaceutical Unit

                              Endo International plc (ENDP) announced that it has begun restructuring its corporate and branded pharmaceutical R&D functions in Malvern, PA and Chestnut Ridge, NY.

                                New Strong Sell Stocks for January 27th

                                Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday

                                  Is BioMarin (BMRN) Well Poised for Growth in 2017?

                                  We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.

                                    Endo (ENDP) Settles Disputes with Federal Trade Commission

                                    Endo International plc (ENDP) announced that it has resolved all disputes with the U.S. Federal Trade Commission (FTC).

                                      Implied Volatility Surging for Endo International (ENDP) Stock Options

                                      Options traders are pricing in a big move for Endo International (ENDP) shares as it has huge implied volatility.

                                        Endo International (ENDP): Can the Stock Rebound in 2017?

                                        Can Endo make a comeback in 2017 seeing that the company is presently in the middle of the drug pricing controversy?

                                          Arpita Dutt headshot

                                          20 States Sue Teva, Mylan & Other Drug Companies for Price Fixing

                                          The lawsuit and the DoJ antitrust probe pose headline risk for generic companies like Mylan (MYL) and Teva (TEVA).

                                            Arpita Dutt headshot

                                            Generic Stocks Feel Pricing Heat, 1st Charges Filed in DoJ Antitrust Probe

                                            Key generic drugmakers including Teva (TEVA) saw their shares slip on news that the first charges have been filed in the investigation related to generic drug pricing.

                                              Endo (ENDP) Inks Deal to Return Belbuca Rights to BioDelivery

                                              Endo (ENDP) announced that it has entered into an agreement to return the rights for Belbuca to BioDelivery (BDSI).

                                                Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs

                                                Mylan (MYL) has revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on integrating acquisitions.

                                                  Ryan McQueeney headshot

                                                  Here's Why Teva Pharmaceutical's (TEVA) Stock Is Down Today

                                                  Shares of Teva Pharmaceutical Industries (TEVA) slipped over 5.8% in morning trading Tuesday after the company announced a change in upper-level management.